Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "GE"

7254 News Found

CKD cases surge to 16.38% in Indians aged 15+
Healthcare | March 17, 2025

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care


Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’
News | March 13, 2025

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure


Aster DM Healthcare promoters reduce share pledge from 99% to 41%
News | March 12, 2025

Aster DM Healthcare promoters reduce share pledge from 99% to 41%

The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Zydus and Gates Foundation to develop world’s first combination vaccine to offer protection against shigellosis and typhoid
News | March 04, 2025

Zydus and Gates Foundation to develop world’s first combination vaccine to offer protection against shigellosis and typhoid

Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine


Amgen opens new technology and innovation site in Hyderabad
Digitisation | February 25, 2025

Amgen opens new technology and innovation site in Hyderabad

Amgen India investment totals $200 million through 2025


Indegene launches AI platform Cortex
Digitisation | February 25, 2025

Indegene launches AI platform Cortex

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain


Briefs: Syngene International and Cipla
Drug Approval | February 23, 2025

Briefs: Syngene International and Cipla

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’


KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
Healthcare | February 21, 2025

KIMS enters into agreement to manage Splendid Hospitals, Hyderabad

Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals


Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
Drug Approval | February 20, 2025

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved